Literature DB >> 7917772

Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

T W Guentert1, N H Holford, J P Pfefen, J Dingemanse.   

Abstract

1. Single oral doses (100-300 mg) and multiple oral doses (100-350 mg 12 hourly for 7 days) of lazabemide were administered to 35 young and 40 elderly healthy subjects. Plasma concentrations of unchanged drug were determined to study the dose-concentration relationship. 2. The elimination phase time course of lazabemide concentrations indicated concentration-dependent elimination after both single and multiple dosing. Nevertheless, maximum concentrations and areas under concentration-time curves increased almost proportionally with dose and accumulation after chronic dosing was less than a factor of 2; steady-state concentrations were achieved by the third day of dosing. The apparent half-life determining accumulation was approximately 8-9 h. 3. Drug absorption commenced rapidly after a dose; two components to the absorption process were detectable in young subjects possibly due to simultaneous administration of multiple tablets at the higher doses. 4. Observations after single and multiple dosing were described with a compartmental model allowing for parallel saturable (population mean +/- s.d.: maximum elimination rate Vmax/F: 2.8 +/- 1.4 mg h-1; concentration at half-maximum elimination Km: 36 +/- 19 micrograms l-1) and first-order (CL/F 16 +/- 3.8 l h-1) elimination pathways. No important difference between the young and the elderly subjects was noted in absorption or disposition parameters of lazabemide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917772      PMCID: PMC1364813          DOI: 10.1111/j.1365-2125.1994.tb04302.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

Review 2.  Clinical pharmacology of monoamine oxidase inhibitors.

Authors:  K D McDaniel
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

3.  A Bayesian approach to nonlinear random effects models.

Authors:  A Racine-Poon
Journal:  Biometrics       Date:  1985-12       Impact factor: 2.571

Review 4.  Clinical pharmacokinetics of ethanol.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

5.  Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

Authors:  N H Holford; T W Guentert; J Dingemanse; R Kettler
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

  5 in total
  1 in total

1.  Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

Authors:  N H Holford; T W Guentert; J Dingemanse; R Kettler
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.